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An emerging coronavirus, SARS-CoV-2, is the causative agent for the ongoing pandemic of
coronavirus disease 2019 (COVID-19), which has caused a worldwide social and economic
disruption. Currently, no antiviral drugs with proven clinical efficacy, or vaccines for its prevention.
Therefore, to combat the pandemic of this novel coronavirus, new effective treatments are urgently
needed. In the process of traditional drug development, developing new drugs from scratch is a timeconsuming process, requires high-investment, and is a high-risk process, which is impractical to face
the immediate global challenge of the SARS-CoV-2 pandemic. Drug repurposing strategy is one
of the effective ways to quickly find a therapeutic agent for COVID-19 Existing medicines, which
already have been tested and proven safe in humans might work for COVID-19 offering a potentially
faster approach for the disease management. Here, we review h the latest research progress in
epidemiology, viral genome, and life cycles of SARS-CoV-2. Further, we describe and discuss some
promising drugs repurposed to target SARS-CoV-2 that are being evaluated in clinical trials.
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INTRODUCTION
Viral diseases continue to emerge and represent a serious
public health problem. In the last two decades, several
viral epidemics have been recorded, including the severe
acute respiratory syndrome coronavirus (SARS-CoV)
from 2002 to 2003, swine flu (H1N1 influenza) in 2009
and Middle East respiratory syndrome coronavirus
(MERS-CoV) that emerged for the first time in Saudi
Arabia in 2012. SARS-CoV that provoked a large-scale
outbreak was reported for the first time in China, with
approximately 8,000 cases and 800 deaths across 37
countries (Peiris et al., 2003), and MERS-CoV had about
2,500 confirmed cases with more than 800 deaths (Zaki
et al., 2012). Meanwhile, H1N1 influenza was estimated
to cause 150,000-600,000 people died worldwide during
the first year the virus circulated. At the end of 2019,
a novel coronavirus, called SAR-CoV-2, emerged in
Wuhan, China, and spread within months to other
regions. All the end of January 2020, the WHO had
declared the disease as a public health emergency of
international concern, and on March 11th, 2020, WHO
formally recognized it as a global pandemic.
The latest and an ongoing SARS- CoV- 2 outbreak,
by surprise, has triggered a humanitarian crisis.The
efficient human to human transmission of SARSCoV-2, through sneezing, coughing, droplet, aerosol,
and followed by human traveling, are the main factors
of its global spread (Lofti et al., 2020; Rabaan et al.,

2020). At the time of this manuscript preparation, the
virus has infected more than 16 million people with
more than 600,000 death. Indonesia has reported more
than 100,000 confirmed cases with 4,600 deaths related
to the SARS-CoV-2, bringing it as one of the countries
in Southeast Asia region hardest hit by the virus (Johns
Hopkins Coronavirus Resource Center, 2020). The case
fatality rate (CFR) of SARS-CoV-2 infection varies
in each country. In Southeast Asia, again, Indonesia
has the highest rate of CFR. Many factors have been
sought to interfere with the fatality case variation, such
as age distribution, healthcare condition, coinfection,
and overlying health conditions. To be aware of,
theelderly and people with an overlying condition such
as cardiovascular disease, diabetes, respiratory disease,
and cancer are more vulnerable to SARS-CoV-2. Even
though CFR of SARS-CoV-2 was higher than influenza
(de Wit et al., 2020; Fauci et al., 2020), it did not reflect
the risk of death since the actual number of infections
was unknown (Roser et al., 2020; Read et al., 2020).
SARS-COV-2: ORIGIN AND VIROLOGY
As suggested by epidemiological evidence, the SARSCoV-2 outbreak began from the city of Wuhan in Hubei
Province of central China. It was thought that the
Huanan seafood and live animal shopping center was
to be one of the places where the novel virus from an
unknown animal source might have crossed the species
barrier to infect humans (Cascella et al., 2020).
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Coronavirus is a large family of viruses that are
commonly found in people and many different species
of animals, including cats, cattle, camels, and bats.
The viruses cause illness ranging from the common
cold to more severe diseases (Cascella et al.,
2020; Walls et al., 2020). Coronaviruses are divided
into four genera, including Alphacoronavirus (α-CoV),
Betacoronavirus (β-CoV), Deltacoronavirus (δ-CoV),
and Gammacoronavirus (γ-CoV). The α- and β-CoV
are able to infect mammals, while γ- and δ-CoV tend to
infect birds (Chan et al., 2013; Ye et al., 2020). SARSCoV-2 belongs to the Betacoronavirus group, similar to
SARS-CoV and MERS-CoV (Lu et al., 2020). Initially,
the new virus was called 2019-nCoV, as it is similar to
the one that caused the SARS outbreak (SARS-CoVs)
with 82% genetically identical (Chan et al., 2020; Lu
et al., 2020). Later, the International Committee on
Taxonomy of Viruses (ICTV) permanently named
it as SARS- CoV-2 virus and the causing disease as
COVID-19. Even though the SARS-CoV-2 genome
has high similarity with SARS-CoV, the Spike protein
of SARS- CoV-2 is quite different from SARS-CoV.
The presence of furin cleavage site in Spike protein of
SARS-CoV-2 is responsible for its efficient spread from
human to human compared to other beta viruses.
SARS-CoV-2 is enveloped and non-segmented positivestranded RNA virus of the order Nidovirales with a
crown-like appearance under an electron microscope
due to the presence of spike glycoproteins on the
envelope. The genome bind to N protein and exist as a
helical ribonucleoprotein complex. On the surface of the
envelope, the homotrimer of S glycoprotein protrudes
as spike glycoprotein, essential for entry into host
cells. S glycoprotein consisted of S1 and S2 subunit.
The S1 subunit binds with cell receptors,, Angiotensinconverting enzyme 2 (ACE2), whereas the S2 subunit
is responsible for the fusion process. The cleavage of S
glycoprotein is mediated by host protease. Besides, the
whole virus structure is 150 to 160 nm in size (Tortorici
& Veesler, 2019; Millet & Whittaker, 2015; Zhou et al.,
2020).
GENOME AND SARS-COV-2 LIFE CYCLE
The first complete genome of SARS-CoV-2, 29.9 kb
in length, was revealed from Wuhan-Hu-1 coronavirus
(WHCV), a strain of SARS-CoV-2 isolated from a
COVID-19 pneumonia patient who was a worker
in the Wuhan seafood market (Wu et al., 2020). The
SARS- CoV-2 has been categorized as subgenus
Sarbecovirus and is closely associated with two SARSlike CoVs (bat- SL-CoVZC45 and bat-SL-CoVZXC21)
originating from the bat (Lu et al., 2020). It has been
known that SARS-CoV-2 is 80% homologous with
SARS-CoV; some enzymes are even have more than
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90% similarity.The MERS-CoV and SARS-CoV-2 share
~50% sequence similarity (Lu et al., 2020). Meanwhile,
the SARS-CoV and SARS-CoV-2 has approximately
72% resemblance in the spike (S) protein, which is
involved in the attachment of virus glycoprotein and host
receptors (Zhang & Holmes, 2020). The SARS-CoV-2
genome contain six open-reading frames (ORFs) and
several extra genes, in which the amino acid sequences
of replicase domains are more than 90% identical to
SARS-CoV. The distinction between these two viruses
is the spike (S) gene (as mentioned above); SARSCoV-2 has a longer S genes than SARS-CoV. Another
sequence similarity to SARS-CoV-2 was detected in
bat coronavirus RNA- dependent RNA polymerase
(BatCoV
RaTG13), which represented more than
96% identical sequence. Therefore, the SARS-CoV-2
might have originated in bats since both SARS-CoV-2
and BatCoV RaTG13 showed the closest phylogenetic
relationship (Zhou et al., 2020).
From recent studies, it has been clearly shown that
SARS- CoV-2 use ACE2 found in the lower respiratory
tract of humans, as receptor - the same cellular entry
receptor, as SARS-CoV (Zhou et al., 2020). SARSCoV-2 through the virion Spike-glycoprotein has a
stronger binding affinity to ACE2 (Walls et al., 2020),
resulting in a much higher incidence of human to
human transmission and causing a global pandemic. To
hijack the target cell, SARS-CoV-2 enters the cells via
endosomal membrane fusion. The virion S-glycoprotein
on the surface of the virus, first mediates attachment to
the cellular receptor, ACE2, on the surface of human
cells. Membrane fusion then occurr where the ACE2–
virus complex translocates to endosomes. Fusion activity
is activated by cleavage of S protein by the endosomal
acid proteases. After virion is taken up into endosomes,
the viral genome RNA is released into the cytoplasm.
The SARS-CoV-2 genomic RNA encoded non-structural
proteins have a critical role in viral RNA synthesis
and structural proteins are necessary for virion
assembly. First, the uncoated RNA is translated into
viral replicase polyproteins, pp1a, and 1ab. By viral
proteinase, pp1a and 1ab polyproteins and then cleaved
into small non-structural proteins to form a replicationtranscription complex (RTC) in a double-membrane
vesicle. Continuously, RTC replicate and synthesize
a nested set of subgenomic negative-strand RNAs on
the plus-strand genome that serve as templates for
mRNA synthesis, which encode accessory proteins
and structural proteins. The full-length negative-strand
template is made as a template for genomic RNA. Viral
nucleocapsids are assembled from genomic RNA and N
protein in the cytoplasm, which is followed by budding
into the lumen of the ERGIC (endoplasmic reticulum
(ER)–Golgi intermediate compartment. Lastly, the
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virion-containing vesicles are fused with the plasma
membrane to release the virus from the cell through
exocytosis (Astuti & Ysrafil, 2020; Shereen et al., 2020).

Drug repositioning of known drugs must be urgently
sought to meet the emerging issues of COVID-19. The
repositioning of drugs has become a popular strategy in
recent years. Compared to traditional drug development
strategies, the strategy is efficient, economical, and
involves less risk (Agrawal, 2015). This approach could
significantly accelerate the development and deployment
of potential therapies for COVID-19 treatment.

Currently, no specific antiviral agent for SARS-CoV-2
has not been found. However, the knowledge of the
SARS- COV-2 origin and replication cycle could help
in recognition of potential drugs based on its possible
inhibitory stage. The entry site, coating, proteolysis
process, RNA dependent RNA polymerase, and viral
ribonucleocapsid assembly are promising targets for
drug repurposing.
PATHOGENESIS
From the cell’s perspective, the SARS-CoV-2 disease
is divided into three phases, which are asymptomatic
phase (initial infection), upper, and conducting airway
response, and progression to ARDS (Wu & McGoogan,
2020). After the initial infection, SAR2-CoV-2 migrate
down to the deeper respiratory tract. This migration
triggers a robust immune response, such as cytokine
production (Mason, 2020). In severe cases, it leads to
alveolar damaged (Qian et al., 2020). About 80% of the
infected patient show no symptom or mild symptom and
do not progress to acute respiratory distress syndrome
(ARDS). However, 20% of infected patients develop
severe diseases, with 2% fatality rate. The elderly,
people with overlay disease, cardiovascular disease, and
hypertension had a higher risk of ARDS progression
because of their diminished or imbalanced immune
response and reduced ability to repair the damaged
epithelium (Mason, 2020; Porcheddu et al., 2020).
Even though the pathogenesis of COVID-19 is yet to be
fully understood, the primary pathogenesis of SARSCoV-2 infection is associated with severe pneumonia,
RNAemia, ground-glass opacity of lung, acute cardiac
injury, and high level of cytokines and chemokines
(Rothan & Byrareddy, 2020). Regarding cytokine, it was
observed that in the severe patient, the IL2, IL6, IL7,
IL10, IP10, MCP1, MIP1α, and TNFα were higher and
presumed to correlate with the disease severity (Huang
et al., 2020; Zhou et al., 2020). For drug repurposing, the
pathogenesis of SARS-CoV-2 is crucial in determining
potential therapeutics, as discussed briefly in the last
section.
DRUG REPURPOSING
INFECTION

FOR

SARS-COV-2

All efforts should be made, including to develop an
effective therapy to manage the SARS-CoV-2 pandemic.
Vaccine development, however, could require at least
12-18 months, and the typical timeline from hit finding
to drug registration of an antiviral is more than ten years.
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There are many investigational programs, and clinical
trials have been initiated to identify an effective
treatment targeting SARS-CoV-2. Clinical trials using
repurposed clinical-stage or approved drugs have been
under investigation for treating COVID-19 patients.
These drugs include; hydroxychloroquine, lopinavir/
ritonavir, and remdesivir. Some other drugs also being
investigated. At the time of writing this article, those
medications are an experimental stage and had not been
licensed or approved to treat SARS-CoV-2 infection.
REMDESIVIR
Synthesized and developed by Gilead Sciences in
2017, remdesivir (GS-5734) was initially developed
as a treatment for Ebola virus infection.
It is
a broad-spectrum class of viral RNA-dependent RNA
polymerases (RdRp) inhibitors against several RNA
viruses. Remdesivir has shown extensive antiviral
activity, in vitro, against a diverse panel of RNA viruses
not only Ebola virus, but also against Marburg, MERSCoV, SARS-CoV, Respiratory syncytial virus, Nipah and
Hendra virus (Lo et al., 2017; Sheahan et al., 2017; Warren
et al., 2016). In the viral life cycle, viral RdRp has a vital
function in viral RNA synthesis. Due to high sequence,
structural conservation, and lack of host homolog, RdRp
presented an attractive target for inhibition of several
RNA virus infection, including SARS-CoV-2.
Remdesivir is a prodrug of 1′-cyano-substituted
adenosine nucleotide analog (NA). During disposition
into the cell target, the prodrugs are metabolized to
the active drug in the triphosphate form (5’-TP). The
active form NAs (GS-441524) is a competitive substrate
for endogenous nucleotides incorporation into viral
RNA by the RdRp, accounting for the antiviral effect.
The mechanism of remdesivir’s antiviral activity is
likely through premature termination of viral RNA
transcription by; first, NA incorporation might cause
termination of RNA synthesis. This action could be
either obligate, i.e., the analog lacks a 3’-OH required for
RNA chain extension, or non-obligate, i.e., the analog
perturbs the structure of product RNA enough to stop
further synthesis by the polymerase. The second mode
of action exist without termination of RNA synthesis, it
possibly over high-number of incorporated NAs into the
nascent RNA. The high incorporation of NAs result in
E-ISSN 2477-0612
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unrecognized RNA as normal Watson-Crick nucleobases
during the following rounds of RNA synthesis from the
NAs-containing template, which ultimately lead to lethal
mutagenesis caused by non-viable genomes (Gordon et
al., 2020).
In non-human primate models, remdesivir had shown
an extensive antiviral activity and an effective treatment
of lethal viruses such as Ebola and Nipah infections
(Lo et al., 2017). Remdesivir decreased lung virus titers
significantly with improvements in pulmonary function
in the SARS-mouse model when administered one day
after the onset of the disease (Sheahan et al., 2020).
Meanwhile, in a rhesus monkey model infected with
MERS-CoV, a treatment of remdesivir 24 hours before
an infection could completely prevent symptoms caused
by MERS-CoV, strongly inhibited viral replications
in the respiratory tract, and prevented the formation
of pulmonary lesions (de Wit et al., 2020; Sheahan et
al., 2017; Sheahan et al., 2020). In the macaque model
of SARS-CoV-2 infection, early remdesivir treatment
showed an extensive reduction in pulmonary damage
and virus titer in bronchoalveolar lavages (Williamson et
al., 2020). Further, a placebo-controlled randomized trial
of remdesivir in 237 patients with severe SARS-CoV-2
infection manifestation showed that earlier treatment
with remdesivir reduced the time of clinical improvement
(Wang et al., 2020). Based on animal and limited clinical
trial researches, the timing of remdesivir intervention
was critical. Thus, a combination of remdesivir, together
with the anti-inflammatory drug for a further clinical
trial, was suggested (Wang et al., 2020). By the time this
article was prepared, remdesivir had been advanced to
a controlled-clinical trial on the United States and other
international sites, in combination with baricitinib (antiinflammatory drug, explained on other potential drugs)
for SARS-CoV-2 infection. The current clinical study
included more than 1000 patients (National Institutes of
Health, 2020).
CHLOROQUINE AND HYDROXYCHLOROQUINE
Chloroquine and hydroxychloroquine has been used to
inhibit the growth of many different viruses, including
influenza A H5N1, human coronavirus OC43, and the
SARS coronavirus (Touret & de Lamballerie, 2020).
Chloroquine exerts its antiviral activity by increasing
the pH of the cellular organelles, which block virion
fusion and uncoating. It also inhibited viral entry by
glycosylation of the cellular receptor of SARS-CoV (Liu
et al., 2020). Chloroquine (N4-(7-Chloro-4-quinolinyl)N1,N1-diethyl-1,4-pentanediamine) were generally safe
with a mild-transient side effect. However, chloroquine
had a narrow therapeutic index, which had been associated
with a life-threatening cardiovascular disorder. The use of
chloroquine has been widely indicated for the prevention
E-ISSN 2477-0612
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and treatment of Plasmodium infection (malaria).
Hydroxychloroquine
(2-[4-[(7-chloroquinolin-4-yl)
amino]pentyl-ethylamino]ethanol) was a derivate
of chloroquine, synthesized by the introduction of a
hydroxyl group into chloroquine. It showed less toxicity
in animals, and therefore, it might be a better drug choice
than chloroquine. Since hydroxychloroquine is a derivate
of chloroquine, it was a straightforward candidate for
drug repurposing to treat the 2019-nCoV infection.
In early 2020, Wang and the team showed that chloroquine
(diphosphate salt) was highly effective at the entry stage
of the virus infection, as well as at the post-entry stage
(Wang et al., 2020). Chloroquine showed half-maximal
effective concentration (EC50) 1.13 μM, half-cytotoxic
concentration (CC50)>100 μM, and selectivity index
(SI=CC50/EC50)>88.50. Compared to remdesivir, which
showed EC50=0.77 μM, CC50>100, and SI>129.87 μM,
chloroquine had slightly lower potential against SARsCoV-2. However, chloroquine has a better safety record,
higher availability, and lesser cost than remdesivir.
Therefore, in terms of safety and access, chloroquine
appeared to be a drug of choice (Liu et al., 2020).
Afterward, several clinical trials had been quickly
followed to test the efficacy and safety of chloroquine
or hydroxychloroquine in the treatment of pneumonia
caused by SARs-CoV-2 infection (Gao et al., 2020). The
result of the trials which included more than 100 patients
was that chloroquine phosphate significantly inhibited
exacerbation of pneumonia, improved lung imaging,
promoted negative virus conversion, and shortened the
disease course compared to control treatment. Based
on these findings, by February 15th, 2020, the National
Health Commission of the People’s Republic of China
recommended chloroquine phosphate for the treatment
of pneumonia caused by SARs-CoV-2 infection.
On the other hand, two clinical trials conducted by
Gautret and his team (2020) supported the evidence
that hydroxychloroquine was an effective medication
in reducing nasopharyngeal viral load in COVID-19
patients, especially for the non-critical condition. The
first was a prospective an open-label non-randomized
trial that included 20 patients in a single treatment arm
(hydroxychloroquine alone, n = 14, or with azithromycin,
n = 6) and 16 patients as a control group. It was
reported that on the sixth-day of post-inclusion, 70% of
hydroxychloroquine-treated patients were virologically
cured comparing with 12.5% in the control group. A
combination with azithromycin increased the effectivity
of viral load reduction (Gautret et al., 2020). The second
trial was a prospective observational study that included
more extensive subject as much of 80 patients. It
showed that the combination of hydroxychloroquine and
azithromycin resulted in a rapid fall of nasopharyngeal
viral load, with 93% on day eighth. Patients were also
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quickly discharged from the infectious unit with an
average length of stay of five days (Gautret et al., 2020).
However, the aforementioned remarkable findings
in the clinical trial of hydroxychloroquine had several
substantial limitations. The results from clinical trials
registered in the Chinese Clinical Trial Registry were
announced, but without any data provided. It made
more difficulties to get a firm conclusion (Touret & de
Lamballerie 2020). Subsequent clinical trials by Philippe
Goutret had not included critically ill patients as the
primary concern of high mortality rate of COVID-19,
small cohort, absence of randomization, no control arm
in the second trials, poor inclusion and exclusion criteria,
and PCR data gaps between control and treatment groups
(Kim et al., 2020; Taccone et al., 2020). Furthermore,
hydroxychloroquine alone or in combination with
azithromycin showed no clinical benefit in severely
COVID-19 patients and for those requiring oxygen
(Mahévas et al., 2020; Molina et al., 2020).

(Cameron et al., 1999). Lopinavir and Ritonavir (brand
name: Norvir) was developed by Abbott Laboratories
(Now: AbbVie) and approved by the FDA in 2000 and
1996, respectively. Although it was initially developed as
an independent antiviral agent, ritonavir co-administered
with other protease inhibitors showed advantageous
properties. Ritonavir inhibiting cytochrome P450 3A4
and prevented the other PIs metabolism, therefore
boosted them (Lv et al., 2015). Lopinavir and ritonavir
also had been used in a combination (code: LPV/r), under
the brand name Kaletra (Mangum & Graham, 2001).

To answer the doubt on hydroxychloroquine use
for COVID-19, Geleris and team (2020) conducted
observational study in New York-Presbyterian Hospital
(NYP)–Columbia University Irving Medical Center
(CUIMC). This study included 1376 patients, 811
(58.9%) of which received hydroxychloroquine, the
median follow-up was of 22.5 days, and 346 patients
(25.1%) developed primary end-point which are
intubation or death. Cox proportional-hazards regression
analysis result showed that there was no significant
association between hydroxychloroquine use and
intubation or death (hazard ratio, 1.04, 95% confidence
interval, 0.82 to 1.32) (Geleris et al., 2020). A clinical
trial by Boulware (2020), randomized, double-blind, and
controlled by placebo, strengthen the result of the above
study. In this study, the efficacy of hydroxychloroquine
for postexposure prophylaxis was tested. As much
as 821 participants were enrolled, 87.6% of which
were reported high-risk contact with COVID-19
confirmed subject. 11.8% of the participant receiving
hydroxychloroquine developed illness or laboratory
confirmation of COVID-19 within 14 days, whereas the
participant of the placebo group was 14.3% confirmed
COVID-19. There was no significant difference between
groups (Boulware et al., 2020). From these two clinical
studies, we may conclude that hydroxychloroquine is not
a drug of choice for COVID-19.
LOPINAVIR/RITONAVIR
Lopinavir and ritonavir are antiretroviral (ARV) drugs
and initially developed as HIV-1 medications. Both are
structurally related and belong to the peptidomimetic
protease inhibitors (PIs) drug class. PIs inhibited
essential viral protein production; thus, immature virions
incapable of further infection process would be produced
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LPV/r is currently one of the four treatment options
that are studied in “Solidarity” international clinical
trials organized by the World Health Organization to
combat COVID-19 (WHO, 2020). LPV/r was used in
the previous SARS and MERS outbreak. Therefore,
it was suggested that it could be considered as one of
the potential therapeutic strategies (Yao et al., 2020). The
rationale of the LPV/r used in COVID-19 was that both
anti-HIV drugs were initially purposed to inhibit 3C like
proteases (3CLpro) of SARS CoV and MERS (Zumla et
al., 2016). SARS-CoV-2 proteinase is an attractive drug
target and highly conserved, compared to SARS-CoV
with 96.1% sequence similarities. However, whether
HIV protease inhibitors could effectively target SARS
CoV 3CLpro is still unclear and debatable, because in fact
that these two enzymes came from two different families.
HIV protease is from the aspartic protease family, and
SARS-CoV-2 CLpro is a member of the cysteine protease
family (Nutho et al., 2020).
Many clinical studies have been done in a short time and
on a small scale for LPV/r effectiveness on COVID-19
patients, and the results are still limited or inconclusive
(Tao et al., 2020). In a previous case study done to
four patients, LPV/r was given and showed promising
effects as initial therapy of COVID-19 (Wang et al.,
2020). Another study also showed a positive effect
of lopinavir on COVID-19 in 10 patients (Liu et al.,
2020). However, a retrospective study that observed
134 novel coronavirus pneumonia showed that there
was no significant difference between LPV/r treated
group (n = 52) and the control group (n = 48) (Chen et
al., 2020; Yao et al. 2020). Because of the conflicting
results, verification study is still needed to be done on a
larger scale to justify whether the treatment with LPV/r
is effective and beneficial for COVID-19 patients.
OTHER POTENTIAL DRUGS
Since drug repurposing mainly aim at shortening
the time for drug discovery by using existing drugs,
computational methods such as in silico and networkbased drug repurposing also became important as a
quick screening tools. These methods identified potential
E-ISSN 2477-0612
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drugs and drugs combination not only synthetic but also
from a natural product (Hijikata et al., 2020; Wrapp et
al. 2020; Wu et al., 2020). In addition, as mentioned
previously, ACE2 as host receptor, 3C-like proteinase
as processed enzyme of viral protein, and 2’-O-Ribose
methyltransferase (nsp16) which important in viral RNA
caps finalization were also potential targets for SARSCoV-2 drug repurposing (Hijikata et al., 2020; Wrapp et
al., 2020).
Based on in silico screening of lisinopril, enalaprilat, and
captopril, which are targeted the ACE as hypertension
drug has been failed to interfere with the receptorbinding domain interaction with SARS-CoV-2 surface
glycoprotein ACE2 (Hijikata et al., 2020). On the same
research, carfilzomib, which is a proteasome inhibitor,
showed promising affinity to SARs-CoV-2 3C-like
proteinase. Similar to carfilzomib, a natural productderived drug, sinefugin, showed interaction with the
conserved area of 2’-O-ribose methyltransferase. In
addition, network proximity analysis pointed out that
silvestrol, also derived from natural products, had
demonstrated a potential binding activity to RNA
helicase of SARS- CoV-2. Moreover, the combination
of toremifene (a cancer drug) with emodin (rheum
tanguticum-derived drug) is potentially used as a SARSCoV-2 inhibitor in multiple mechanisms (Zhou et al.,
2020; Ho et al., 2007). However, further experiments are
still needed to be done before going to a clinical trial.
Drug repurposing screening also performed based
on SARS-CoV-2 pathogenesis information such as
inflammatory response. To note, pro-inflammatory
cytokines such as IL 6 could be a potential target for
drug repurposing. However, there is the main concern
that anti-inflammatory use might increase secondary
infection risk and delay the elimination of SARSCoV-2. Other things, anti-inflammation medication
targeted only specific inflammatory factors, thus might
not effective in stopping cytokine storm in SARSCoV-2 patients (Zhang, 2020). As SARS-CoV-2 patient
observation, the use of corticosteroids did not support
the stop of lung injury (Russell et al., 2020). However,
the use of tocilizumab, which target IL 6 receptors is
suggested to have improved oxygenation and reduced
the opacity lung lesion based on CT scan results and gave
the light for further trial (Xu et al., 2020). Currently, a
clinical trial of tocilizumab had registered (Zhang, 2020).
In addition to tocilizumab, it is reported that baricitinid,
a Janus kinase inhibitor, an inhibitor of cytokine-release,
in a limited clinical study (24 patients) of its safety and
efficacy improved the clinical and laboratory parameters
on moderate COVID-19 patients compared to baseline
(Cantini et al., 2020). Recently, a clinical trial on the
combination of baricitinid together with remdesivir is
ongoing.
E-ISSN 2477-0612
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CONCLUDING REMARK
In facing the pandemic caused by the new coronavirus,
SARS-CoV-2, all global researchers are working and
sharing the data regarding virus character and result of
drug repurposing. Besides vaccine development and
rapid diagnostic tools, virus characteristics and drugs
screening hold essential roles in stopping the virus
transmission. Even though some of the drugs discussed
above have been applied for treating the patient, a further
clinical trial is required to assess their efficacy and
safety. A combination of antiviral, such as remdesivir
and the anti-inflammatory drug, could be potential for
COVID-19 treatment.
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